New Acute Myeloid Leukemia Hope: Amgen Acquires Dark Blue Therapeutics [Los Angeles Times (CA)]
Amgen Inc. (AMGN)
Last amgen inc. earnings: 4/30 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
investors.amgen.com
Company Research
Source: Los Angeles Times
United Kingdom, advancing first-in-class, small molecule-targeted protein degraders for oncology, through a transaction valued at up to $840 million. The investment adds to Amgen's portfolio an investigational small molecule that targets and degrades proteins that drive specific types of acute myeloid leukemia, a fast-growing blood cancer. “Acute myeloid leukemia remains one of the most difficult cancers to treat, and we see an urgent need for new mechanisms capable of changing the trajectory of this disease,” said Jay Bradner, M.D. , executive vice president of research and development at Amgen, in a statement. “This acquisition complements and extends our research in targeted protein degradation and leukemia therapeutics, advancing our strategy to invest early in rising medicines for novel therapeutic targets.” The acquisition was attractive because it focuses on medicines with AML. Preclinical data in leukemia models demonstrate promising anti-cancer activity and mechanistic di
Show less
Read more
Impact Snapshot
Event Time:
AMGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
AMGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
AMGN alerts
High impacting Amgen Inc. news events
Weekly update
A roundup of the hottest topics
AMGN
News
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Argus from $360.00 to $400.00. They now have a "buy" rating on the stock.MarketBeat
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Guggenheim from $305.00 to $347.00. They now have a "neutral" rating on the stock.MarketBeat
- Amgen (NASDAQ:AMGN) had its price target raised by analysts at Deutsche Bank Aktiengesellschaft from $285.00 to $295.00. They now have a "hold" rating on the stock.MarketBeat
- CVS Health to swap Amgen and Lilly's bone drugs with biosimilars in commercial formularies [Seeking Alpha]Seeking Alpha
- Jim Cramer on Amgen: “The Biotech Really Impressed Me With a Very Strong Pipeline” [Yahoo! Finance]Yahoo! Finance
AMGN
Earnings
- 2/3/26 - Beat
AMGN
Sec Filings
- 2/3/26 - Form 8-K
- 1/30/26 - Form 8-K
- 11/21/25 - Form 4
- AMGN's page on the SEC website